Perspective Therapeutics Soars: RBC Boosts Target to $16!

miércoles, 4 de junio de 2025, 5:42 am ET1 min de lectura
CATX--
Perspective Therapeutics, Inc. surged 5.83% in premarket trading, with RBC Capital maintaining its outperform rating and raising its target price to $16. Multiple Wall Street firms also updated their ratings and target prices, ranging from $6 to $18.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios